Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Diabet Med ; 24(6): 600-6, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17381499

ABSTRACT

AIMS: Slowly digestible starch is associated with beneficial health effects. The glucose-lowering drug acarbose has the potential to retard starch digestion since it inhibits alpha-amylase and alpha-glucosidases. We tested the hypothesis that a low dose of acarbose delays the rate of digestion of rapidly digestible starch without reducing its bioavailability and thereby increasing resistant starch flux into the colon. METHODS: In a crossover study, seven healthy males ingested corn pasta (50.3 g dry weight), naturally enriched with (13)C, with and without 12.5 mg acarbose. Plasma glucose and insulin concentrations, and (13)CO(2) and hydrogen excretion in breath were monitored for 6 h after ingestion of the test meals. Using a primed continuous infusion of D-[6,6-(2)H(2)] glucose, the rate of appearance of starch-derived glucose was estimated, reflecting intestinal glucose absorption. RESULTS: Areas under the 2-h postprandial curves of plasma glucose and insulin concentrations were significantly decreased by acarbose (-58.1 +/- 8.2% and -72.7 +/- 7.4%, respectively). Acarbose reduced the overall 6-h appearance of exogenous glucose (bioavailability) by 22 +/- 7% (mean +/-se) and the 6-h cumulative (13)CO(2) excretion by 30 +/- 6%. CONCLUSIONS: These data show that in healthy volunteers a low dose of 12.5 mg acarbose decreases the appearance of starch-derived glucose substantially. Reduced bioavailability seems to contribute to this decrease to a greater extent than delay of digestion. This implies that the treatment effect of acarbose could in part be ascribed to the metabolic effects of colonic starch fermentation.


Subject(s)
Acarbose/pharmacokinetics , Blood Glucose/analysis , Hypoglycemic Agents/pharmacokinetics , Insulin/blood , Starch/metabolism , Adult , Biological Availability , Breath Tests , Carbon Dioxide/analysis , Cross-Over Studies , Digestion/drug effects , Humans , Hydrogen/analysis , Male , Postprandial Period
2.
Eur J Clin Invest ; 34(6): 417-21, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15200493

ABSTRACT

BACKGROUND: Small intestinal and oro-cecal transit time (OCTT) is determined for clinical diagnostics and research purposes. Experimental protocols used vary with respect to the inclusion of a subsequent meal during the test period. This study was conducted to elucidate whether the ingestion of a subsequent meal during the test period influences the OCTT of the test meal. MATERIALS AND METHODS: The OCTT of a liquid test meal, measured with the lactose-[(13)C]ureide breath test, was compared between four groups of healthy volunteers (n = 36) who consumed the subsequent meal at different time points. Also, the OCTT was determined twice in eight subjects; a subsequent meal was ingested after 180 min (test A) and after 360 min (test B). RESULTS: An apparently meal-related increase in median OCTT was observed. The OCTT of the eight volunteers measured in test A (210; 210-349 median; quartiles) was significantly shorter than that found in test B (345; 300-375 min, P = 0.016). As result of the ingestion of the subsequent meal at 180 min the OCTT was shortened by 90; 64-116 min in 7/8 subjects. CONCLUSION: These data indicate that the ingestion of a subsequent meal affects the OCTT of a liquid test meal. This phenomenon could be explained by the increased intestinal motility in response to a meal, and should be taken into account when designing protocols for measurements of the OCTT and in the interpretation of small intestinal absorption studies.


Subject(s)
Eating/physiology , Gastrointestinal Transit/physiology , Lactose/analogs & derivatives , Urea/analogs & derivatives , Adult , Breath Tests/methods , Cecum/metabolism , Female , Gastrointestinal Motility/physiology , Humans , Intestinal Absorption/physiology , Intestine, Small/metabolism , Male
3.
Am J Gastroenterol ; 87(11): 1629-30, 1992 Nov.
Article in English | MEDLINE | ID: mdl-1442688

ABSTRACT

We describe two patients with chronic diarrhea associated with dysgonic fermenter-3 (DF-3) infection. One patient had common variable hypogammaglobulinemia and the other hand chronic idiopathic neutropenia and human immunodeficiency virus infection. Specific stool culture techniques were necessary to isolate DF-3. The organism was sensitive to clindamycin, tetracycline, and trimethoprim-sulfamethoxazole. Antibiotic therapy eradicated the organism and the diarrhea resolved in both patients. DF-3 is a little-recognized organism associated with diarrhea in the immunocompromised patient. It should be suspected when routine evaluation and stool cultures are not diagnostic.


Subject(s)
Agammaglobulinemia/complications , Diarrhea/microbiology , Gram-Negative Anaerobic Cocci , Gram-Negative Bacterial Infections/microbiology , HIV Infections/complications , Immunocompromised Host , Adult , Agammaglobulinemia/immunology , Female , HIV Infections/immunology , Humans , Male , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...